- Risankizumab was associated with improved efficacy compared with placebo at 16 weeks in this phase 3 randomized controlled trial (RCT).
- It also is associated with improved efficacy compared with treatment withdrawal at 1 and 2 years for patients with moderate to severe plaque psoriasis.
Why this matters
- Risankizumab appears to represent a promising method for maintaining clinical efficacy in these patients.
- At week 16, vs placebo, risankizumab was associated with higher rates of:
- ≥90% improvement in the Psoriasis Area and Severity Index: 73.2% vs 2.0% (P<.001>
- Static Physician’s Global Assessment (sPGA) score 0/1: 83.5% vs 7.0% (P<.001>
- 1 year: 87.4% vs 61.3%.
- 2 years: 81.1% vs 7.1% (P<.001 for both>
- 507 patients with moderate to severe plaque psoriasis were randomly assigned to risankizumab (n=407) or placebo (n=100).
- At week 28, a total of 336 responders were randomly allocated to risankizumab (n=111) or treatment withdrawal (n=225).
- Funding: AbbVie, Boehringer Ingelheim.
- Lack of QoL measurements.